Introduction
It has been established that low-density lipoprotein cholesterol (LDL-C) is a central therapeutic target for coronary artery disease (CAD) 1) . Although statins reduce the risk of CAD by 30-40%, cardiovascular events, known as "residual risks" 2) , can continue to occur during intensive LDL-lowering therapy, and research aims to identify new therapeutic targets beyond LDL-C. The well-characterized residual risks following statin treatment include a high level of triglycerides (TGs), a low level of high-density lipoprotein cholesterol (HDL-C), uncontrolled diabetes mellitus, hypertension, obesity and lifestyle factors, such as smoking and inactivity. Such factors are not controlled with statin treatment. There is an inverse correlation between the circulating HDL-C level and the risk of CAD 3) . Even after statin treatment, the inverse correlation between the incidence of cardiovascular the analysis.
Preparation of the HDL and LDL Fractions
The serum samples were thawed on ice and incubated with 20% polyethethylene glycol (PEG) (SigmaAldrich, MO, USA) solution in 200 mmol/L of glycine buffer to remove apolipoprotein B (apoB)-containing lipoproteins, as previously described 18) . In brief, each serum sample was mixed with PEG solution (100:40) and incubated for 15 minutes at room temperature. The samples were then centrifuged at 4,000 rpm for 20 minutes to precipitate all apoB-containing lipoproteins, and the supernatant was kept as the HDL fraction (PEG-HDL). Phosphate-buffered saline (PBS) was incubated with PEG solution and centrifuged according to the same methods as the serum, and the supernatant was used as a control (PEG-PBS). LDL was isolated from pooled human plasma using ultracentrifugation (1.020-1.063) 19) . Acetyl LDL was generated by incubating LDL with acetic anhydride 20) , then used in the cholesterol efflux assay.
Lipid Analysis
The serum lipid levels were measured enzymatically using a commercially available kit from WAKO (Osaka, Japan). The serum and HDL-associated apolipoprotein A-I (apoA-I), apoA-II and apoE levels were events and the circulating HDL-C level still holds 4) . HDL exhibits a variety of cardiovascular protective effects by promoting reverse cholesterol transport (RCT) from the vascular wall to the liver 5) . HDL particles also possess several antiatherogenic functions, such as anti-inflammatory, antiapoptotic, antithrombotic and immunomodulating effects 6) . Therefore, it is believed that HDL-raising therapy can reduce the incidence of cardiovascular events. However, large clinical trials using cholesteryl ester transfer protein (CETP) inhibitors have failed to document the efficacy of HDL-raising therapy, despite a marked increase in the serum HDL-C level and a decrease in the serum LDL-C level 7) . Therefore, both raising the HDL level and improving the quality of functional HDL have become interesting topics of discussion in HDL-targeting therapy. Under pathological conditions, HDL particles have been reported to lose their antiatherogenic function and convert into dysfunctional HDL, which promotes inflammation and oxidation 8, 9) . The HDL-raising effects of statins are variable in contrast to their comparable LDL-lowering effects 10) . Pitavastatin is a unique statin that increases the HDL-C level more significantly than other strong statins [10] [11] [12] [13] . Furthermore, pitavastatin improves event-free survival following percutaneous coronary intervention 13) . The mechanisms by which pitavastatin increases the HDL-C level [14] [15] [16] are partially understood; however, the effects of pitavastatin on the quality of HDL remain unknown. In this study, we investigated qualitative and quantitative changes in HDL during pitavastatin treatment. To this end, we evaluated the cholesterol efflux capacity of HDL, the first step in RCT, and the antioxidant properties of the paraoxonase-1 (PON-1) and plateletactivating factor acetylhydrolase (PAF-AH) activities.
Materials and Methods

Patients
This investigation conformed to the principles outlined in the Declaration of Helsinki. All patients gave their written informed consent, and the clinical study was approved by the Institutional Review Board of Kobe University Graduate School of Medicine. A total of 30 patients with dyslipidemia, as defined by the Japan Atherosclerosis Society guidelines 17) , were enrolled in this study. The backgrounds of the participants are described in Table 1 . The patients were treated with 2 mg of pitavastatin daily for four weeks, and serum was obtained pre-and post-pitavastatin treatment. Blood samples were collected after overnight fasting, and the serum was stored at −80 ℃ until 
PON-1 and PAF-AH Activities
The PON-1 activity was analyzed spectrophotometrically with PEG-HDL (HDL-associated PON-1), as previously reported 22) . Two individual PON-1 activities were evaluated. The paraoxonase activity was measured with paraoxon (Sigma-Aldrich, MO, USA) as a substrate, whereas the arylesterase activity was measured with phenylacetate (Sigma-Aldrich, MO, USA) as a substrate. The HDL-associated PAF-AH activity was measured using a commercially available kit (Cayman Chemicals, MI, USA).
Statistical Analysis
All values are presented as the mean±SD. Comparisons between the parameters of pre-and postpitavastatin treatment were made with paired Stumeasured using a commercially available ELISA kit (ASSAYPRO, MO, USA). The lipoprotein profiles were determined using HPLC (LipoSEARCH ® ) at Skylight Biotech, Inc. (Akita, Japan), according to the specified procedure 21) . The levels of HDL-phospholipids, total cholesterol (TC), and free cholesterol (FC) were measured with PEG-HDL using a commercially available kit from WAKO (Osaka, Japan). The level of HDLcholesteryl ester (CE) was calculated by subtracting the level of HDL-FC from the level of HDL-TC.
Cholesterol Efflux Study
The cholesterol efflux studies were performed as previously described 18) . The human monocyte cell line THP-1 (RIKEN, Tsukuba, Japan) was cultured in RPMI 1640 medium (Wako, Osaka, Japan) containing 10% fetal bovine serum. The cells were harvested in 24-well plates and differentiated into macrophages using 200 nmol/L of phorbor myristate acetate (Sigma-Aldrich, MO, USA) for 72 hours. Next, the adherent macrophages were incubated with 25 μg/mL of acetyl LDL and 1 μCi of [ 3 H] cholesterol (PerkinElmer Life Science, MA, USA) for 24 hours, followed by treatment with 10 μmol/L of Liver X receptor agonist TO901317 (Sigma-Aldrich, MO, USA) for 16 hours. The cells were then incubated with either 2.8% PEG-HDL or PEG-PBS in RPMI 1640 medium with Total-C; total-cholesterol, HDL-C; high density lipoprotein-cholesterol, LDL-C; low density lipoproteincholesterol, apoA-I; apolipoprotein A-I, PL; phospholipid, FC; free cholesterol, CE; cholesteryl ester, HDL fraction was purified with polyethylene glycol precipitation. data represent mean±SD HDL-associated paraoxonase activity was increased in the dyslipidemic patients by 9% (23.2±9.7 vs 25.0± 10.5 pmol/min/mL PEG-HDL; p＜0.05) (Fig. 3A,  3B ). The HDL-associated arylesterase activity was increased by 11% (58.7±20 vs 63.1±19 pmol/min/ mL PEG-HDL; p＜0.05) (Fig. 3C, 3D ). Neither the HDL-associated paraoxonase or arylesterase activity standardized according to the serum apoA-I level changed during pitavastatin treatment (data not shown). Similarly, the HDL-associated PAF-AH activity did not change during pitavastatin treatment (71.5 ±21.2 vs 71.2±25.6 pmol/min/mL PEG-HDL; p = 0.92) (Fig. 4A, 4B ). These data suggest that pitavastatin enhances serum antioxidant properties by increasing the number of HDL particles that possess PON-1 activities. dent's t-test (two-tailed) using the GraphPad Prism Software program.
Results
Pitavastatin Increased the Serum HDL-C and HDL-Phospholipids Levels
The lipid profiles of the patients ( Table 1 ) preand post-pitavastatin treatment are shown in Table 2 . Pitavastatin significantly decreased the serum Total-C, LDL-C and TG levels and increased the serum HDL-C levels in the dyslipidemic patients by 9% compared to the baseline values. Pitavastatin treatment led to a significant increase in the phospholipid content of the HDL fraction of 7.8%. The HPLC analysis revealed that the peak HDL fraction deviated to the left, indicating an increase in the number of large HDL particles (Fig. 1A, B) . The levels of ApoA-I, apoA-II and apoE and the FC/CE ratio of HDL did not change during pitavastatin treatment. Taken together, pitavastatin increased the number of phospholipid-rich large HDL particles without modifying the apolipoprotein distribution.
Pitavastatin Increased the Serum Cholesterol Efflux Capacity
The cholesterol efflux capacity of HDL isolated via PEG precipitation was performed using THP-1 macrophages incubated with acetyl LDL and the Liver X receptor agonist in order to mimic the macrophage phenotypes in atherosclerotic lesions. We confirmed that TO901317 treatment increased the mRNA expressions of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1), while acetyl LDL treatment decreased the scavenger receptor class B type I (SR-BI) mRNA expression in THP-1 macrophages (data not shown). Pitavastatin significantly increased the PEG-HDL-specific cholesterol efflux capacity in the dyslipidemic patients by 8.6% (6.6±1.4 vs 7.1± 1.7%; p＜0.05) (Fig. 2A, 2B) . The cholesterol efflux capacity standardized according to the serum apoA-I level was increased during pitavastatin treatment (Fig. 2) , indicating that the increased HDL level contributed to the increased efflux capacity. These findings suggest that pitavastatin increases the amount of HDL particles that are functionally preserved with a cholesterol efflux capacity.
Pitavastatin Enhanced Serum Antioxidant Properties
The PON-1 activity is widely used to evaluate the antioxidant properties of HDL 6, 23, 24) . Therefore, the HDL-associated PON-1 activities in the pre-and post-pitavastatin serum samples were measured. The antioxidative capacity of HDL, as evaluated in a cellfree assay, is attenuated in patients with acute coronary syndrome 27) . Therefore, changes in the quality of functional HDL are closely related to the risk of cardiovascular disease. In this study, pitavastatin treatment increased the cholesterol efflux capacity and the PON-1 activity in association with antioxidant properties in conditioned HDL isolated from dyslipidemic patients. These effects occurred in parallel with an increase in the serum HDL-C level. Taken together, pitavastatin increased the amount of functional HDL without attenuating the HDL quality.
Several plausible explanations have been proposed for the molecular mechanisms underlying the effects of pitavastatin on HDL. Previous studies have indicated that pitavastatin increases apoA-I production both in vitro 14) and in vivo 28) . In addition,
Discussion
Although a large number of epidemiological studies have documented a strong inverse association between the plasma HDL-C level and the incidence of cardiovascular events, the benefits of HDL-raising pharmaceutical intervention remain controversial 7, 25) . The relationship between the plasma HDL-C level and the risk of cardiovascular events is often explained by the functional quality of HDL, including cholesterol efflux and the antioxidative, anti-inflammatory and antiproliferative properties 6) . Cholesterol efflux from macrophages is the rate-limiting first step in RCT from a diseased vessel wall to the liver. A recent study demonstrated that the cholesterol efflux capacity of HDL is an independent negative risk factor for CAD 26) . Additionally, Patel et al. reported that the . Given that pitavastatin increases the amount of mature phospholipid-rich HDL and decreases the amount of nascent pre-beta HDL 15) , we speculate that the increased level of mature HDL induced by pitavastatin contributes to enhancing the efflux capacity, most likely via the actions of ABCG1. In brief, pitavastatin increases the amount of HDL via a dual mechanism through which it attenuates HDL catabolism and promotes HDL synthesis.
Khera et al. recently reported that statin treatment did not increase the serum cholesterol efflux capacity in their cohort study 26) . However, the serum cholesterol efflux capacity was measured at only one time point and pitavastatin was not included in the medication regimen. Pitavastatin has a greater capacity pitavastatin has been reported to increase the ABCA1 expression in vitro 29) . Pitavastatin also decreases the expression of endothelial lipase, which increases not only the quantity of HDL, but also the HDL particle size by increasing the amount of phospholipid content 16) . The phospholipid-rich HDL particles generated by EL suppression exert anti-inflammatory and antioxidative effects 22) . As for cholesterol efflux, in the macrophages used in the efflux method in this study, both ABCA1 and ABCG1 were upregulated by the LXR agonist, and SR-BI was downregulated by acetyl LDL treatment. The macrophages ABCA1 and ABCG1 play crucial roles in in vivo reverse cholesterol transport 30) . ABCA1 primarily promotes cholesterol efflux through the actions of lipid-poor apoA-I and nascent HDL, whereas ABCG1 and SR-BI mediate efflux 23, 26) . In the present study, changes in the cholesterol efflux capacity were not correlated with changes in the PON-1 activity (data not shown). Furthermore, the activity of another antioxidant enzyme, PAF-AH, was not affected by pitavastatin. Previous reports have also shown that the cholesterol efflux capacity is not always associated with antioxidant properties 26, 27) . These findings indicate that each parameter representing HDL antiatherosclerotic properties is independent, and further studies are needed to identify the most important and relevant markers of the quality of functional HDL.
The results of clinical trials of CETP inhibitors are confusing with respect to HDL-raising therapies. Two CETP inhibitors, torcetrapib 7) and dalcetrapib 36) , failed to reduce the incidence of cardiovascular events despite raising the HDL-C levels. It has been reported that the HDL elevated by CETP inhibition or deficiency possesses normal or enhanced cholesterol efflux 37) and antioxidant properties 38) , indicating that dysfunctional HDL does not affect the overall results. In general, statins inhibit the CETP activity 10) , and the increased HDL level induced by statins may be partially due to CETP inhibition. Therefore, both statins and CETP inhibitors increase the amount of functionally preserved HDL. However, there is a large discrepancy in clinical outcomes between statins and CETP inhibitors, the precise mechanisms of which remain unknown. These data imply that raising the level of functional HDL via pharmaceutical intervention alone does not lead to improved clinical outto increase the HDL-C level than other statins 13) , and the present study directly assessed changes in the efflux capacity pre-and post-pitavastatin treatment.
PON-1 is an HDL-associated protein that exerts antioxidative effects on HDL. The PON-1 activity is evaluated using several individual substrates. The substrate of the paraoxonase activity assay is paraoxon, while that of the arylesterase activity assay is phenylacetate, and there is a positive relationship between the results of these assays 22) . Previous studies have shown that statins increase the PON-1 mass and activity by up to 40% 32) . In the present study, pitavastatin increased the HDL associated-paraoxonase activity by 10% and the HDL associated-arylesterase activity by 14%, which dominated the increased serum HDL-C level. This finding may be partially due to the fact that pitavastatin directly upregulates the PON-1 expression in cultured hepatocytes 33) . In this study, we selected pitavastatin because it has a greater capacity to raise the HDL level than other statins; however, the HDL-raising effects of pitavastatin are shared by other statins 10) . Clinical studies of both pravastatin 34) and rosuvastatin 35) have shown that regression of the atherosclerotic plaque volume is positively correlated with changes in the HDL-C level. Combining these clinical data with our results, the raised HDL level observed during statin therapy may be beneficial for reducing the amount of atherosclerotic lesions by increasing the cholesterol efflux capacity and antioxidant properties.
It has not been elucidated yet whether the statininduced changes observed in the HDL antiatherogenic properties are physiologically relevant to preventing A B comes in patients with cardiovascular disease. Clinical studies of two other novel CETP inhibitors are currently ongoing, the results of which may provide additional insight. Several limitations are associated with the present study. This study consisted of a small number of subjects, and we did not compare the effects of pitavastatin with those of other statins. In addition, the duration of pitavastatin treatment was not long, although several clinical studies have shown that pitavastatin treatment increases the HDL level by over 10% for longer periods 12, 16) . In our study cohort, few participants exhibited low levels of HDL-C, and the effects of statins may have been greater if the study was conducted among low HDL-C patients only. Further studies should be performed to evaluate these issues.
In conclusion, pitavastatin treatment increases the serum HDL-C levels in association with increases in the cholesterol efflux capacity and PON-1 activity in dyslipidemic patients. In general, pitavastatin increases the amount of HDL particles while functionally preserving antiatherosclerotic properties. The increased quantity and quality of HDL may at least, in part, contribute to the antiatherosclerotic effects of this statin.
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